Pediatrix Medical Group shares fall as Q1 revenue declines

Published 06/05/2025, 11:14
Pediatrix Medical Group shares fall as Q1 revenue declines

FORT LAUDERDALE - Pediatrix Medical (TASE:BLWV) Group, Inc. (NYSE:MD) reported first quarter earnings that beat analyst expectations, but saw its revenue decline YoY, leading to a 6.5% drop in its stock price.

The healthcare services provider posted adjusted earnings per share of $0.33 for the first quarter of 2025, surpassing the analyst estimate of $0.24. However, revenue fell to $458.36 million from $495.1 million in the same quarter last year, though it still exceeded the consensus estimate of $451.44 million.

Pediatrix attributed the revenue decline primarily to practice dispositions, which was partially offset by a 6.2% increase in same-unit net revenue. The company reported that same-unit revenue from net reimbursement-related factors increased by 4.6%, while revenue attributable to patient volume grew by 1.6%.

"Our strong first quarter results reflect same-unit top-line outperformance versus our expectations, continued steady cost management and the successful results of the portfolio restructuring we completed last year," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group.

Despite the revenue decline, Pediatrix raised its full-year 2025 Adjusted EBITDA outlook from a range of $215 million to $235 million to a new range of $220 million to $240 million. The company reported first quarter Adjusted EBITDA of $49 million.

Ordan added, "While we are raising our guidance, we remain mindful of the uncertainty that we face in the healthcare industry and the broad economic turbulence that is challenging virtually all companies."

The company’s shares fell 6.5% following the earnings release, suggesting investors may be focusing on the revenue decline despite the earnings beat and raised guidance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.